Skye Bioscience Statistics
Total Valuation
Skye Bioscience has a market cap or net worth of $22.19 million. The enterprise value is -$3.27 million.
Important Dates
The next estimated earnings date is Thursday, May 7, 2026, after market close.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Skye Bioscience has 33.38 million shares outstanding. The number of shares has increased by 8.71% in one year.
| Current Share Class | 33.38M |
| Shares Outstanding | 33.38M |
| Shares Change (YoY) | +8.71% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 1.46% |
| Owned by Institutions (%) | 12.60% |
| Float | 21.20M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.11 |
| P/TBV Ratio | 1.11 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.30, with a Debt / Equity ratio of 0.01.
| Current Ratio | 3.30 |
| Quick Ratio | 3.14 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -126.85% and return on invested capital (ROIC) is -81.78%.
| Return on Equity (ROE) | -126.85% |
| Return on Assets (ROA) | -71.93% |
| Return on Invested Capital (ROIC) | -81.78% |
| Return on Capital Employed (ROCE) | -289.25% |
| Weighted Average Cost of Capital (WACC) | 19.75% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$4.66M |
| Employee Count | 12 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Skye Bioscience has paid $5,400 in taxes.
| Income Tax | 5,400 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -58.18% in the last 52 weeks. The beta is 2.86, so Skye Bioscience's price volatility has been higher than the market average.
| Beta (5Y) | 2.86 |
| 52-Week Price Change | -58.18% |
| 50-Day Moving Average | 0.77 |
| 200-Day Moving Average | 2.08 |
| Relative Strength Index (RSI) | 46.53 |
| Average Volume (20 Days) | 1,135,457 |
Short Selling Information
The latest short interest is 1.57 million, so 4.71% of the outstanding shares have been sold short.
| Short Interest | 1.57M |
| Short Previous Month | 967,400 |
| Short % of Shares Out | 4.71% |
| Short % of Float | 7.42% |
| Short Ratio (days to cover) | 1.44 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -58.16M |
| Pretax Income | -55.92M |
| Net Income | -55.92M |
| EBITDA | -57.44M |
| EBIT | -58.16M |
| Earnings Per Share (EPS) | -$1.41 |
Full Income StatementBalance Sheet
The company has $25.74 million in cash and $273,646 in debt, with a net cash position of $25.46 million or $0.76 per share.
| Cash & Cash Equivalents | 25.74M |
| Total Debt | 273,646 |
| Net Cash | 25.46M |
| Net Cash Per Share | $0.76 |
| Equity (Book Value) | 20.02M |
| Book Value Per Share | 0.60 |
| Working Capital | 18.89M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$43.06 million and capital expenditures -$6,312, giving a free cash flow of -$43.07 million.
| Operating Cash Flow | -43.06M |
| Capital Expenditures | -6,312 |
| Depreciation & Amortization | 723,352 |
| Net Borrowing | n/a |
| Free Cash Flow | -43.07M |
| FCF Per Share | -$1.29 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Skye Bioscience does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -8.71% |
| Shareholder Yield | -8.71% |
| Earnings Yield | -251.99% |
| FCF Yield | -194.06% |
Analyst Forecast
The average price target for Skye Bioscience is $15.00, which is 2,155.98% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $15.00 |
| Price Target Difference | 2,155.98% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | 6.94% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 8, 2023. It was a reverse split with a ratio of 1:250.
| Last Split Date | Sep 8, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:250 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
